CardiOx Corporation   Report issue

For profit Phase 3
Founded: Dublin OH United States (2006)
Status: No NME R&D (2006)

Organization Overview

First Clinical Trial
2012
NCT02516319
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

Medical Director, Cardiox Corporation

Active Ingredients

Drugs in Phase 3 Trials (2)

indocyanine green (ic-green) (2 trials)

lft-0002 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hepatic Insufficiency (Phase 3)

Liver Failure (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2